253 related articles for article (PubMed ID: 27094814)
1. Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme.
Lawrence GL; Wang H; Lahra M; Booy R; McINTYRE PB
Epidemiol Infect; 2016 Aug; 144(11):2382-91. PubMed ID: 27094814
[TBL] [Abstract][Full Text] [Related]
2. Evolving meningococcal immunization strategies.
Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
[TBL] [Abstract][Full Text] [Related]
3. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Lally N; Ahoure M; Denehy E; Koehler A; Flood L; Marshall H
Lancet Infect Dis; 2022 Jul; 22(7):1011-1020. PubMed ID: 35427492
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil.
Tauil Mde C; Carvalho CS; Vieira AC; Waldman EA
Braz J Infect Dis; 2014; 18(4):379-86. PubMed ID: 24698710
[TBL] [Abstract][Full Text] [Related]
6. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
Marshall HS; Lally N; Flood L; Phillips P
Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
[TBL] [Abstract][Full Text] [Related]
7. Surveillance of invasive meningococcal disease in the south of Brazil: considerations of immunization programme.
Silveira MM; Crespo da Silva PA; Conrad NL; Oliveira TL; Hartwig DD; Trotter C
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33544069
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec.
De Wals P; De Serres G; Niyonsenga T
JAMA; 2001 Jan; 285(2):177-81. PubMed ID: 11176810
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
[TBL] [Abstract][Full Text] [Related]
10. Impact of meningococcal C conjugate vaccine in the UK.
Balmer P; Borrow R; Miller E
J Med Microbiol; 2002 Sep; 51(9):717-722. PubMed ID: 12358061
[TBL] [Abstract][Full Text] [Related]
11. Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015.
MacNeil JR; Blain AE; Wang X; Cohn AC
Clin Infect Dis; 2018 Apr; 66(8):1276-1281. PubMed ID: 29126310
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
De Wals P; Deceuninck G; Boulianne N; De Serres G
JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
[TBL] [Abstract][Full Text] [Related]
13. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
[TBL] [Abstract][Full Text] [Related]
14. Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.
de Waure C; Miglietta A; Nedovic D; Mereu G; Ricciardi W
Hum Vaccin Immunother; 2016; 12(2):467-73. PubMed ID: 26308192
[TBL] [Abstract][Full Text] [Related]
15. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.
Mbaeyi S; Pondo T; Blain A; Yankey D; Potts C; Cohn A; Hariri S; Shang N; MacNeil JR
JAMA Pediatr; 2020 Sep; 174(9):843-851. PubMed ID: 32687590
[TBL] [Abstract][Full Text] [Related]
17. Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.
Wang X; Shutt KA; Vuong JT; Cohn A; MacNeil J; Schmink S; Plikaytis B; Messonnier NE; Harrison LH; Clark TA; Mayer LW
J Infect Dis; 2015 Jun; 211(12):1887-94. PubMed ID: 25556253
[TBL] [Abstract][Full Text] [Related]
18. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
[TBL] [Abstract][Full Text] [Related]
19. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study.
Campbell H; Andrews N; Parikh SR; White J; Edelstein M; Bai X; Lucidarme J; Borrow R; Ramsay ME; Ladhani SN
Lancet Child Adolesc Health; 2022 Feb; 6(2):96-105. PubMed ID: 34883094
[TBL] [Abstract][Full Text] [Related]
20. Global practices of meningococcal vaccine use and impact on invasive disease.
Ali A; Jafri RZ; Messonnier N; Tevi-Benissan C; Durrheim D; Eskola J; Fermon F; Klugman KP; Ramsay M; Sow S; Zhujun S; Bhutta Z; Abramson J
Pathog Glob Health; 2014 Jan; 108(1):11-20. PubMed ID: 24548156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
